Publication | Open Access

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial

Breast OncologyPam50 SubtypesMedicineImmunologyImmune ModulationCherlob TrialImmune Checkpoint InhibitorBreast CancerCancer TreatmentImmunotherapyOncologyRadiation OncologyEndocrine-related Cancer